<DOC>
	<DOC>NCT00383903</DOC>
	<brief_summary>The purpose of this study is to determine the appropriate regimen of GSK HRV vaccine for concomitant administration with EPI vaccines to infants in South Africa.</brief_summary>
	<brief_title>Evaluate Safety &amp; Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infants born after a normal gestation period (&gt;=36 weeks), between 5 and 10 weeks of age at Dose 1 with confirmed negative HIV status of the subject's mother. Written informed consent was obtained from the parent/guardian of the subject before study entry. History of allergic disease/polio disease, Confirmed or suspected immunosuppressive or immunodeficient condition, Clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator, Received treatment prohibited by the protocol. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>